Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Amortizatization of Intangibles: 2016-2025

Historic Amortizatization of Intangibles for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Sep 2025 value amounting to $1.7 million.

  • Rocket Pharmaceuticals' Amortizatization of Intangibles fell 9.19% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 27.82%. This contributed to the annual value of $8.1 million for FY2024, which is 24.16% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Amortizatization of Intangibles stood at $1.7 million for Q3 2025, which was down 24.37% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Amortizatization of Intangibles registered a high of $3.3 million during Q4 2023, and its lowest value of -$801,000 during Q4 2021.
  • For the 3-year period, Rocket Pharmaceuticals' Amortizatization of Intangibles averaged around $2.3 million, with its median value being $2.2 million (2024).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Amortizatization of Intangibles plummeted by 486.29% in 2021 and then soared by 1,560.90% in 2023.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Amortizatization of Intangibles stood at -$801,000 in 2021, then spiked by 234.96% to $1.1 million in 2022, then spiked by 202.96% to $3.3 million in 2023, then tumbled by 62.66% to $1.2 million in 2024, then decreased by 9.19% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $2.2 million for Q2 2025, and $2.2 million during Q1 2025.